Invited article: Lost in a jungle of evidence: We need a compass

Neurology

Volumn 71, Issue 20, 2008, Pages 1634-1638

  French, Jacqueline ^a,c   Gronseth, Gary ^b,c  

^a NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF KANSAS   (United States)

^c AMERICAN ACADEMY OF NEUROLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; BOTULINUM TOXIN; PLACEBO; RIVASTIGMINE; WARFARIN;

ARTICLE; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; CONTROL GROUP; EMBOLISM; EVIDENCE BASED MEDICINE; HEADACHE; HIGH RISK PATIENT; HUMAN; INTERVENTION STUDY; METHODOLOGY; MIGRAINE; PRIORITY JOURNAL; RECURRENT DISEASE; SECONDARY PREVENTION; STROKE; THYMECTOMY; UNSPECIFIED SIDE EFFECT; INFORMATION PROCESSING; REVIEW;

CLINICAL TRIALS AS TOPIC; DATA COLLECTION; EVIDENCE-BASED MEDICINE; HUMANS;

EID: 58149384567     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/01.wnl.0000336533.19610.1b     Document Type: Article

References (12)

1. Chimowitz MI, Kokkinos J, Strong J, et al. The Warfarin-Aspirin Symptomatic Intracranial Disease Study. Neurology 1995;45:1488-1493.
2. Mohr JP, Thompson JL, Lazar RM, et al. A comparison of warfarin and aspirin for the prevention of recurrent isch-emic stroke. N Engl J Med 2001;345:1444-1451.
3. Lohr KN. Rating the strength of scientific evidence: relevance for quality improvement programs. Int J Qual Health Care 2004;16:9-18.
4. Kunz R, Oxman AD. The unpredictability paradox: review of empirical comparisons of randomised and non-randomised clinical trials. BMJ 1998;317:1185-1190.
5. Failure of extracranial-intracranial arterial bypass to reduce the risk of ischemic stroke: results of an international randomized trial. The EC/IC Bypass Study Group. N Engl J Med 1985;313:1191-1200.
6. Gronseth GS, Barohn RJ. Practice parameter: thymectomy for autoimmune myasthenia gravis (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2000; 55:7-15.
7. Schulz KF. Subverting randomization in controlled trials. JAMA 1995;274:1456-1458.
8. Rosler M, Anand R, Cicin-Sain A, et al. Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomized controlled trial. BMJ 1999;318:633-638.
9. Silberstein S, Mathew N, Saper J, Jenkins S, for the BOTOX Migraine Clinical Research Group. Botulinum toxin type A as a migraine preventive treatment. Headache 2000;40:445-450.
10. Naumann M, So Y, Argoff C, et al. Assessment: Botuli-num neurotoxin in the treatment of autonomic disorders and pain (an evidence-based review): Report of the Therapeutics and Technology assessment Subcommittee of the American Academy of Neurology. Neurology 2008;70: 1707-1714.
11. Viera AJ, Bangdiwala SI. Eliminating bias in randomized controlled trials: importance of allocation concealment and masking. Fam Med 2007;39:132-137.
12. Temple R, Ellenberg SS. Placebo-controlled trials and active-control trials in the evaluation of new treatments: part 1: ethical and scientific issues. Ann Intern Med 2000; 133:455-463.